U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428252) titled 'Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma' on Feb. 05.
Brief Summary: The aim of this prospective clinical study is to evaluate the prognostic and predictive significance of the gastrointestinal microbiome in patients with metastatic malignant melanoma treated with first-line immunotherapy using immune checkpoint inhibitors (PD-1 inhibitors and CTLA-4 inhibitors). Although immunotherapy has significantly improved survival outcomes, treatment response remains unpredictable and a substantial proportion of patients develop immune-related adverse events, pseudoprogression, or hyperprogres...